Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
glimepiride + metformin (Laboratorios Pharmedic)
- Development stage
- Phase 4
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Amiride M is a fixed-dose combination oral hypoglycemic agent developed and marketed by Laboratorio Pharmedic for the management of type 2 diabetes mellitus. It consists of glimepiride, a second-generation sulfonylurea, and metformin, a biguanide. Glimepiride acts by stimulating insulin release from pancreatic beta cells through the closure of ATP-sensitive potassium channels. Metformin works primarily by decreasing hepatic glucose production, decreasing intestinal absorption of glucose, and improving insulin sensitivity by increasing peripheral glucose uptake and utilization. This combination provides complementary mechanisms to improve glycemic control in patients whose hyperglycemia is not adequately managed by monotherapy.
- Brand names
- Amiride M
- Other names
- glimepiride/metforminglimeprida + metforminaglimepiride + metformin
02
Targets
PRKAG2 (Protein kinase AMP-activated non-catalytic subunit gamma 2)KCNJ11 (Atp-sensitive inward rectifier potassium channel 11)ND1 (Mitochondrial electron transport chain complex I)SUR2A (ATP-binding cassette sub-family C member 9)AMPK (Adenosine monophosphate–activated protein kinase)KATP channel (ATP-sensitive potassium channel)
Beyond the preview
Go deeper on glimepiride + metformin (Laboratorios Pharmedic).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on glimepiride + metformin (Laboratorios Pharmedic).